Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Immunosuppressive treatment and the risk of diabetes in rheumatoid arthritis.

Lillegraven S, Greenberg JD, Reed GW, Saunders K, Curtis JR, Harrold L, Hochberg MC, Pappas DA, Kremer JM, Solomon DH.

PLoS One. 2019 Jan 23;14(1):e0210459. doi: 10.1371/journal.pone.0210459. eCollection 2019.

2.

Risk of diabetes mellitus associated with disease-modifying antirheumatic drugs and statins in rheumatoid arthritis.

Ozen G, Pedro S, Holmqvist ME, Avery M, Wolfe F, Michaud K.

Ann Rheum Dis. 2017 May;76(5):848-854. doi: 10.1136/annrheumdis-2016-209954. Epub 2016 Nov 11.

PMID:
27836820
3.

Association between disease-modifying antirheumatic drugs and diabetes risk in patients with rheumatoid arthritis and psoriasis.

Solomon DH, Massarotti E, Garg R, Liu J, Canning C, Schneeweiss S.

JAMA. 2011 Jun 22;305(24):2525-31. doi: 10.1001/jama.2011.878.

PMID:
21693740
4.
5.

Brief Report: Intensification to Triple Therapy After Treatment With Nonbiologic Disease-Modifying Antirheumatic Drugs for Rheumatoid Arthritis in the United States From 2009 to 2014.

Sparks JA, Krumme AA, Shrank WH, Matlin OS, Brill G, Pezalla EJ, Choudhry NK, Solomon DH.

Arthritis Rheumatol. 2016 Jul;68(7):1588-95. doi: 10.1002/art.39617.

6.
7.

Risk of venous thromboembolism in patients with rheumatoid arthritis: initiating disease-modifying antirheumatic drugs.

Kim SC, Solomon DH, Liu J, Franklin JM, Glynn RJ, Schneeweiss S.

Am J Med. 2015 May;128(5):539.e7-17. doi: 10.1016/j.amjmed.2014.11.025. Epub 2014 Dec 20.

8.
9.

Cardiovascular disease in patients with rheumatoid arthritis: results from the QUEST-RA study.

Naranjo A, Sokka T, Descalzo MA, Calvo-Alén J, Hørslev-Petersen K, Luukkainen RK, Combe B, Burmester GR, Devlin J, Ferraccioli G, Morelli A, Hoekstra M, Majdan M, Sadkiewicz S, Belmonte M, Holmqvist AC, Choy E, Tunc R, Dimic A, Bergman M, Toloza S, Pincus T; QUEST-RA Group.

Arthritis Res Ther. 2008;10(2):R30. doi: 10.1186/ar2383. Epub 2008 Mar 6.

10.

Biologics or tofacitinib for rheumatoid arthritis in incomplete responders to methotrexate or other traditional disease-modifying anti-rheumatic drugs: a systematic review and network meta-analysis.

Singh JA, Hossain A, Tanjong Ghogomu E, Kotb A, Christensen R, Mudano AS, Maxwell LJ, Shah NP, Tugwell P, Wells GA.

Cochrane Database Syst Rev. 2016 May 13;(5):CD012183. doi: 10.1002/14651858.CD012183. Review.

PMID:
27175934
11.

Disease-modifying antirheumatic drug use and the risk of incident hyperlipidemia in patients with early rheumatoid arthritis: a retrospective cohort study.

Desai RJ, Eddings W, Liao KP, Solomon DH, Kim SC.

Arthritis Care Res (Hoboken). 2015 Apr;67(4):457-66. doi: 10.1002/acr.22483.

12.

Economic Burden and Treatment Patterns of Cycling between Conventional Synthetic Disease-modifying Antirheumatic Drugs Among Biologic-treated Patients with Rheumatoid Arthritis.

Betts KA, Griffith J, Ganguli A, Li N, Douglas K, Wu EQ.

Clin Ther. 2016 May;38(5):1205-16. doi: 10.1016/j.clinthera.2016.03.013. Epub 2016 Apr 2.

PMID:
27045991
13.

Comparative cancer risk associated with methotrexate, other non-biologic and biologic disease-modifying anti-rheumatic drugs.

Solomon DH, Kremer JM, Fisher M, Curtis JR, Furer V, Harrold LR, Hochberg MC, Reed G, Tsao P, Greenberg JD.

Semin Arthritis Rheum. 2014 Feb;43(4):489-97. doi: 10.1016/j.semarthrit.2013.08.003. Epub 2013 Sep 5.

PMID:
24012043
14.

Health Care Effect of Disease-Modifying Antirheumatic Drug Use on Patients with Rheumatoid Arthritis.

Boytsov NN, Bhattacharya R, Saverno K, Dixon L, Abbott PL, Zhang X, Gaich CL, Nair R.

J Manag Care Spec Pharm. 2019 Aug;25(8):879-887. doi: 10.18553/jmcp.2019.25.8.879.

15.

Delay in initiation of DMARD or anti-inflammatory therapy in patients newly diagnosed with rheumatoid arthritis: An analysis of United States Military Health System TRICARE beneficiaries.

Kimsey L, Weissman JS, Patel A, Drew A, Koehlmoos T, Sparks JA.

Semin Arthritis Rheum. 2019 Apr;48(5):821-827. doi: 10.1016/j.semarthrit.2018.07.003. Epub 2018 Jul 18.

PMID:
30190154
16.

Predictors of treatment initiation with tumor necrosis factor-α inhibitors in patients with rheumatoid arthritis.

Desai RJ, Rao JK, Hansen RA, Fang G, Maciejewski ML, Farley JF.

J Manag Care Spec Pharm. 2014 Nov;20(11):1110-20.

18.

Changes in use of disease-modifying antirheumatic drugs for rheumatoid arthritis in the United States during 1983-2009.

Kim SC, Yelin E, Tonner C, Solomon DH.

Arthritis Care Res (Hoboken). 2013 Sep;65(9):1529-33. doi: 10.1002/acr.21997.

19.

Patterns of the initiation of disease-modifying antirheumatic drugs in incident rheumatoid arthritis: a German perspective based on nationwide ambulatory drug prescription data.

Steffen A, Holstiege J, Klimke K, Akmatov MK, Bätzing J.

Rheumatol Int. 2018 Nov;38(11):2111-2120. doi: 10.1007/s00296-018-4161-7. Epub 2018 Oct 10.

20.

Examining Time to Initiation of Biologic Disease-modifying Antirheumatic Drugs and Medication Adherence and Persistence Among Texas Medicaid Recipients With Rheumatoid Arthritis.

Kim G, Barner JC, Rascati K, Richards K.

Clin Ther. 2016 Mar;38(3):646-54. doi: 10.1016/j.clinthera.2016.01.022. Epub 2016 Feb 18.

PMID:
26899313

Supplemental Content

Support Center